Testing Immunotherapy Before Surgery for Sarcomatoid Mesothelioma
Tests nivolumab and ipilimumab before surgery in adults with sarcomatoid mesothelioma.
Key facts
- Who runs it
- Alliance for Clinical Trials in Oncology
- Where
- Aberdeen, Anchorage, Arroyo Grande, Aurora, Bellevue, Bellingham, Bend, Boise, Burbank, Carson City, Centralia, Chadds Ford, Chicago, Clackamas, Coos Bay, Dallas, Danville, DeKalb, Durham, Edmonds, Effingham, Elkton, Everett, Fort Worth, Fruitland, Geneva, Glenview, Grayslake, Henderson, Hood River, Issaquah, Jacksonville, Kennewick, Kingman, La Jolla, Lacey, Lake Forest, Las Vegas, Lewes, Longview, Mattoon, Meridian, Millville, Minneapolis, Missoula, Mount Vernon, Nampa, Napa, Newark, Newberg, Oregon City, Orland Park, Pahrump, Phoenix, Portland, Raleigh, Redmond, Rehoboth Beach, Reno, Renton, Richardson, Rochester, Santa Rosa, Scottsdale, Seattle, Sedro-Woolley, Shelton, Spokane, Twin Falls, Urbana, Vancouver, Walla Walla, Warrenville, Wilmington, Yakima, Yelm, and Yorkville, United StatesSee the 132 sites
- Trial code
- Registry title
- Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 26 people, planned
- Started
- 27 Nov 2024
- Expected to end
- 15 Dec 2026
- Type of study
- Interventional
- Treatments tested
- Nivolumab
- Ipilimumab
- Surgical Procedure
- Computed Tomography
- Magnetic Resonance Imaging
- Positron Emission Tomography
- Record updated
- 5 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early-stage sarcomatoid or mostly sarcomatoid pleural mesothelioma. Immunotherapy with nivolumab and ipilimumab is given before surgery.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Sarcomatoid, or mostly sarcomatoid (more than 50%) biphasic, pleural mesothelioma, stage I-IIIA.
- Earlier treatment
- No earlier treatment for this cancer. No hormone or chemotherapy drugs, except hormones for other conditions such as diabetes.
Main reasons for not taking part
- Cancer that cannot be removed by surgery, or poor candidates for surgery
- Cancer that has spread to the chest wall, peritoneum, other side of the chest, mediastinal organs, spine or certain lymph nodes
- History of symptomatic interstitial lung disease
- Active autoimmune disease, with a few listed exceptions
- Pregnant or nursing women
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Sarcomatoid or sarcomatoid-dominant (> 50%) biphasic, pleural mesothelioma
- Stage: I-IIIA disease per Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours 8th edition
- Measurable disease or non-measurable disease as defined
- No prior treatment which would be considered treatment for the primary neoplasm or impact the primary endpoint
- No treatment with hormones or other chemotherapeutic agents except for hormones administered for non-disease-related conditions (e.g., insulin for diabetes and or hormonal therapy for breast, prostate cancer etc.)
- Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown; Therefore, for women of childbearing potential only, a negative pregnancy test done =< 14 days prior to registration is required
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 or Karnofsky >= 60%
- Absolute neutrophil count (ANC) >= 1,000/mm\^3
- Leukocytes >= 2,000/mm\^3
- Platelet count >= 100,000/mm\^3
- Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance >= 40 mL/min
- Total bilirubin =<1.5 x ULN, except patients with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dl
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
- Alkaline (alk) phosphatase (phos) =< 3.0 x ULN
- No active, known or suspected autoimmune disease except for vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
- No active systemic infection requiring therapy, as well as positive tests for hepatitis B surface antigen or hepatitis C antibody
- No history of any other condition that may require the initiation of anti-tumor necrosis factor alpha (TNFalpha) therapies or other immunosuppressant medications during the study
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- STEP 2 ELIGIBILITY CRITERIA: Completion of at least 1 cycle of treatment and not have an unresolved adverse event that would preclude surgery
- STEP 2 ELIGIBILITY CRITERIA: No evidence of progression that would preclude resection
- STEP 2 ELIGIBILITY CRITERIA: ECOG performance status =< 2 or Karnofsky >= 60%
- STEP 2 ELIGIBILITY CRITERIA: Predicted forced expiratory volume in 1 second (FEV1) > 35% and postoperative predicted diffusion capacity of the lung for carbon monoxide (DLCO) > 35%
- STEP 2 ELIGIBILITY CRITERIA: Registration to step 2 no less than 21 days and no more than 90 days after the last dose of neoadjuvant therapy
Who cannot take part
- No patients deemed to be unresectable or poor surgical candidates
- No patients with a history of symptomatic interstitial lung disease
- No patients with chest wall invasion, peritoneal spread, contralateral pleural involvement, mediastinal organ involvement, vertebral involvement, or metastases to contralateral intrathoracic lymph nodes, or any supraclavicular nodes
Where in United States
- Providence Regional Cancer System-AberdeenAberdeen, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Alaska Breast Care and Surgery LLCAnchorage, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Alaska Oncology and Hematology LLCAnchorage, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Alaska Women's Cancer CareAnchorage, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Anchorage Associates in Radiation MedicineAnchorage, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Katmai Oncology GroupAnchorage, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Providence Alaska Medical CenterAnchorage, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Anchorage Radiation Therapy CenterAnchorage, United StatesContact: Aaron Mansfield, MDNo longer taking part
- PCR OncologyArroyo Grande, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Rush-Copley Medical CenterAurora, United StatesContact: Tanmay Sahai (principal investigator)Taking people
- Overlake Medical CenterBellevue, United StatesContact: Aaron Mansfield, MDNo longer taking part
- PeaceHealth Saint Joseph Medical CenterBellingham, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Saint Charles Health SystemBend, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Saint Luke's Cancer Institute - BoiseBoise, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Providence Saint Joseph Medical Center/Disney Family Cancer CenterBurbank, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Carson Tahoe Regional Medical CenterCarson City, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Providence Regional Cancer System-CentraliaCentralia, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Christiana Care Health System-Concord Health CenterChadds Ford, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Northwestern UniversityChicago, United StatesContact: Young Kwang Chae (principal investigator)Taking people
- University of Chicago Comprehensive Cancer CenterChicago, United StatesContact: Hedy L. Kindler (principal investigator)Taking people
- Clackamas Radiation Oncology CenterClackamas, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Providence Cancer Institute Clackamas ClinicClackamas, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Bay Area HospitalCoos Bay, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- UT Southwestern Simmons Cancer Center - RedBirdDallas, United StatesContact: David B. Nelson (principal investigator)Taking people
- UT Southwestern/Simmons Cancer Center-DallasDallas, United StatesContact: David B. Nelson (principal investigator)Taking people
- Carle at The RiverfrontDanville, United StatesContact: Tanmay Sahai (principal investigator)Taking people
- Northwestern Medicine Cancer Center KishwaukeeDeKalb, United StatesContact: Young Kwang Chae (principal investigator)Taking people
- Duke Cancer Center SouthpointDurham, United StatesContact: Jeffrey M. Clarke (principal investigator)Taking people
- Duke University Medical CenterDurham, United StatesContact: Jeffrey M. Clarke (principal investigator)Taking people
- Swedish Cancer Institute-EdmondsEdmonds, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Carle Physician Group-EffinghamEffingham, United StatesContact: Tanmay Sahai (principal investigator)Taking people
- Christiana Care - Union HospitalElkton, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Providence Regional Cancer PartnershipEverett, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- UT Southwestern/Simmons Cancer Center-Fort WorthFort Worth, United StatesContact: David B. Nelson (principal investigator)Taking people
- Saint Luke's Cancer Institute - FruitlandFruitland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Northwestern Medicine Cancer Center DelnorGeneva, United StatesContact: Young Kwang Chae (principal investigator)Taking people
- Northwestern Medicine Glenview Outpatient CenterGlenview, United StatesContact: Young Kwang Chae (principal investigator)Taking people
- Northwestern Medicine Grayslake Outpatient CenterGrayslake, United StatesContact: Young Kwang Chae (principal investigator)Taking people
- Comprehensive Cancer Centers of Nevada - HendersonHenderson, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Comprehensive Cancer Centers of Nevada-Horizon RidgeHenderson, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Comprehensive Cancer Centers of Nevada-Southeast HendersonHenderson, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Oncology Las Vegas - HendersonHenderson, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Urology Specialists of Nevada - Green ValleyHenderson, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Cancer and Blood Specialists-HendersonHenderson, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Las Vegas Cancer Center-HendersonHenderson, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Las Vegas Urology - Green ValleyHenderson, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Las Vegas Urology - PebbleHenderson, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Providence Hood River Memorial HospitalHood River, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Swedish Cancer Institute-IssaquahIssaquah, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Mayo Clinic in FloridaJacksonville, United StatesContact: Aaron S. Mansfield (principal investigator)Taking people
- Kadlec Clinic Hematology and OncologyKennewick, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Kingman Regional Medical CenterKingman, United StatesContact: John A. Ellerton (principal investigator)Taking people
- UC San Diego Moores Cancer CenterLa Jolla, United StatesContact: Lyudmila A. Bazhenova (principal investigator)Taking people
- Providence Regional Cancer System-LaceyLacey, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Northwestern Medicine Lake Forest HospitalLake Forest, United StatesContact: Young Kwang Chae (principal investigator)Taking people
- Alliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Comprehensive Cancer Centers of NevadaLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Comprehensive Cancer Centers of Nevada - Central ValleyLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Comprehensive Cancer Centers of Nevada - NorthwestLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Comprehensive Cancer Centers of Nevada - Town CenterLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Comprehensive Cancer Centers of Nevada-SummerlinLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Hope Cancer Care of NevadaLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Oncology Las Vegas - TenayaLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- OptumCare Cancer Care at CharlestonLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- OptumCare Cancer Care at Fort ApacheLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- OptumCare Cancer Care at MountainViewLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Radiation Oncology Centers of Nevada CentralLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Radiation Oncology Centers of Nevada SoutheastLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Summerlin Hospital Medical CenterLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Sunrise Hospital and Medical CenterLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- University Medical Center of Southern NevadaLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Urology Specialists of Nevada - CentralLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Urology Specialists of Nevada - NorthwestLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Urology Specialists of Nevada - SouthwestLas Vegas, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Ann M Wierman MD LTDLas Vegas, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Las Vegas Cancer Center-Medical CenterLas Vegas, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Las Vegas Prostate Cancer CenterLas Vegas, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Las Vegas Urology - Cathedral RockLas Vegas, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Las Vegas Urology - PecosLas Vegas, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Las Vegas Urology - Smoke RanchLas Vegas, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Las Vegas Urology - SunsetLas Vegas, United StatesContact: Aaron Mansfield, MDNo longer taking part
- University Cancer CenterLas Vegas, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Beebe Medical CenterLewes, United StatesContact: Aaron Mansfield, MDNo longer taking part
- PeaceHealth Saint John Medical CenterLongview, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Carle Physician Group-Mattoon/CharlestonMattoon, United StatesContact: Tanmay Sahai (principal investigator)Taking people
- Saint Luke's Cancer Institute - MeridianMeridian, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Beebe South Coastal Health CampusMillville, United StatesContact: Aaron Mansfield, MDNo longer taking part
- University of Minnesota/Masonic Cancer CenterMinneapolis, United StatesContact: Robert A. Kratzke (principal investigator)Taking people
- Saint Patrick Hospital - Community HospitalMissoula, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Skagit Regional Health Cancer Care CenterMount Vernon, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Saint Luke's Cancer Institute - NampaNampa, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Providence Queen of The ValleyNapa, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Christiana Care Health System-Christiana HospitalNewark, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Delaware Clinical and Laboratory Physicians PANewark, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Helen F Graham Cancer CenterNewark, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Medical Oncology Hematology Consultants PANewark, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Providence Newberg Medical CenterNewberg, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Providence Willamette Falls Medical CenterOregon City, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Northwestern Medicine Orland ParkOrland Park, United StatesContact: Young Kwang Chae (principal investigator)Taking people
- Hope Cancer Care of Nevada-PahrumpPahrump, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Mayo Clinic Hospital in ArizonaPhoenix, United StatesContact: Aaron S. Mansfield (principal investigator)Taking people
- Providence Portland Medical CenterPortland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Providence Saint Vincent Medical CenterPortland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Duke Cancer Center RaleighRaleigh, United StatesContact: Jeffrey M. Clarke (principal investigator)Taking people
- Saint Charles Health System-RedmondRedmond, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Beebe Health CampusRehoboth Beach, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Renown Regional Medical CenterReno, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Saint Mary's Regional Medical CenterReno, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Radiation Oncology AssociatesReno, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Valley Medical CenterRenton, United StatesContact: John A. Ellerton (principal investigator)Taking people
- UT Southwestern Clinical Center at Richardson/PlanoRichardson, United StatesContact: David B. Nelson (principal investigator)Taking people
- Mayo Clinic in RochesterRochester, United StatesContact: Aaron S. Mansfield (principal investigator)Taking people
- Providence Medical Foundation - Santa RosaSanta Rosa, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Providence Santa Rosa Memorial HospitalSanta Rosa, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Mayo Clinic in ArizonaScottsdale, United StatesContact: Aaron S. Mansfield (principal investigator)Taking people
- Swedish Medical Center-Ballard CampusSeattle, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Swedish Medical Center-Cherry HillSeattle, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Swedish Medical Center-First HillSeattle, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- PeaceHealth United General Medical CenterSedro-Woolley, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Providence Regional Cancer System-SheltonShelton, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Cancer Care Northwest - Spokane SouthSpokane, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Cancer Care Northwest-North SpokaneSpokane, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Cancer Care Northwest-ValleySpokane, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Saint Luke's Cancer Institute - Twin FallsTwin Falls, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Carle Cancer CenterUrbana, United StatesContact: Tanmay Sahai (principal investigator)Taking people
- PeaceHealth Southwest Medical CenterVancouver, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Providence Saint Mary Regional Cancer CenterWalla Walla, United StatesContact: Alison K. Conlin (principal investigator)Taking people
- Northwestern Medicine Cancer Center WarrenvilleWarrenville, United StatesContact: Young Kwang Chae (principal investigator)Taking people
- Christiana Care Health System-Wilmington HospitalWilmington, United StatesContact: Aaron Mansfield, MDNo longer taking part
- North Star Lodge Cancer Center at Yakima Valley Memorial HospitalYakima, United StatesContact: John A. Ellerton (principal investigator)Taking people
- Providence Regional Cancer System-YelmYelm, United StatesContact: Aaron Mansfield, MDNo longer taking part
- Rush-Copley Healthcare CenterYorkville, United StatesContact: Tanmay Sahai (principal investigator)Taking people
About the trial
What the trial wants to find out
This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.
The group in the trial
- Treatment (nivolumab, ipilimumab, surgery)Treatment being tested
Patients receive nivolumab IV, ipilimumab IV, and may undergo surgery on study. Patients also undergo CT or MRI and PET throughout the trial.
Treatment: Nivolumab, Ipilimumab, Surgical Procedure, Computed Tomography, Magnetic Resonance Imaging, and Positron Emission Tomography
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Official Title Neoadjuvant Immunotherapy in Sarcomatoid Mesothelioma
- Plain-language title
- Testing Immunotherapy Before Surgery for Sarcomatoid MesotheliomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 August 2026